252 related articles for article (PubMed ID: 25152312)
21. A Review of Molecular and Genetic Diagnostics of Myeloid Malignancies with Emphasis on Diagnostics in Bosnia and Herzegovina.
Kurtovic-Kozaric A; Islamagic E; Asic A; Mehinovic-Cavcic L; Besic L; Sahinbegovic H; Komic H; Kurtovic S; Burazerovic L
Acta Med Acad; 2021 Apr; 50(1):175-196. PubMed ID: 34075772
[TBL] [Abstract][Full Text] [Related]
22. The role of mutations in epigenetic regulators in myeloid malignancies.
Shih AH; Abdel-Wahab O; Patel JP; Levine RL
Nat Rev Cancer; 2012 Sep; 12(9):599-612. PubMed ID: 22898539
[TBL] [Abstract][Full Text] [Related]
23. Germ line predisposition to myeloid malignancies appearing in adulthood.
Crysandt M; Brings K; Beier F; Thiede C; Brümmendorf TH; Jost E
Expert Rev Hematol; 2018 Aug; 11(8):625-636. PubMed ID: 29958021
[TBL] [Abstract][Full Text] [Related]
24. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia.
Cervera N; Itzykson R; Coppin E; Prebet T; Murati A; Legall S; Vey N; Solary E; Birnbaum D; Gelsi-Boyer V
Am J Hematol; 2014 Jun; 89(6):604-9. PubMed ID: 24595958
[TBL] [Abstract][Full Text] [Related]
25. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies.
Makishima H; Jankowska AM; Tiu RV; Szpurka H; Sugimoto Y; Hu Z; Saunthararajah Y; Guinta K; Keddache MA; Putnam P; Sekeres MA; Moliterno AR; List AF; McDevitt MA; Maciejewski JP
Leukemia; 2010 Oct; 24(10):1799-804. PubMed ID: 20724984
[No Abstract] [Full Text] [Related]
26. Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies.
Damm F; Nguyen-Khac F; Fontenay M; Bernard OA
Leukemia; 2012 Sep; 26(9):2027-31. PubMed ID: 22484420
[TBL] [Abstract][Full Text] [Related]
27. Detection of copy number alterations in acute myeloid leukemia and myelodysplastic syndromes.
Jacoby MA; Walter MJ
Expert Rev Mol Diagn; 2012 Apr; 12(3):253-64. PubMed ID: 22468816
[TBL] [Abstract][Full Text] [Related]
28. Genetic and molecular characterization of myelodysplastic syndromes and related myeloid neoplasms.
Patel B; Hirsch C; Clemente M; Sekeres M; Makishima H; Maciejewski JP
Int J Hematol; 2015 Mar; 101(3):213-8. PubMed ID: 25690487
[TBL] [Abstract][Full Text] [Related]
29. The molecular basis of myeloid malignancies.
Kitamura T; Inoue D; Okochi-Watanabe N; Kato N; Komeno Y; Lu Y; Enomoto Y; Doki N; Uchida T; Kagiyama Y; Togami K; Kawabata KC; Nagase R; Horikawa S; Hayashi Y; Saika M; Fukuyama T; Izawa K; Oki T; Nakahara F; Kitaura J
Proc Jpn Acad Ser B Phys Biol Sci; 2014; 90(10):389-404. PubMed ID: 25504228
[TBL] [Abstract][Full Text] [Related]
30. Mutant molecules of interest in myeloproliferative neoplasms: introduction.
Tefferi A
Acta Haematol; 2008; 119(4):192-3. PubMed ID: 18566535
[No Abstract] [Full Text] [Related]
31. The landscape of myeloid neoplasms with isochromosome 17q discloses a specific mutation profile and is characterized by an accumulation of prognostically adverse molecular markers.
Meggendorfer M; Haferlach C; Zenger M; Macijewski K; Kern W; Haferlach T
Leukemia; 2016 Jul; 30(7):1624-7. PubMed ID: 26859077
[No Abstract] [Full Text] [Related]
32. Five important advances in hematopathology.
Shi M; Xiao R; Woda BA; Yu H
Arch Pathol Lab Med; 2014 Mar; 138(3):410-9. PubMed ID: 24576034
[TBL] [Abstract][Full Text] [Related]
33. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
Haferlach C; Bacher U; Schnittger S; Alpermann T; Zenger M; Kern W; Haferlach T
Genes Chromosomes Cancer; 2012 Apr; 51(4):328-37. PubMed ID: 22162288
[TBL] [Abstract][Full Text] [Related]
34. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
Smith CA; Fan G
Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
[TBL] [Abstract][Full Text] [Related]
35. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia.
Boultwood J; Perry J; Pellagatti A; Fernandez-Mercado M; Fernandez-Santamaria C; Calasanz MJ; Larrayoz MJ; Garcia-Delgado M; Giagounidis A; Malcovati L; Della Porta MG; Jädersten M; Killick S; Hellström-Lindberg E; Cazzola M; Wainscoat JS
Leukemia; 2010 May; 24(5):1062-5. PubMed ID: 20182461
[No Abstract] [Full Text] [Related]
36. Analytical Validation of a 37-Gene Next-Generation Sequencing Panel for Myeloid Malignancies and Review of Initial Findings Incorporating Updated 2022 Diagnostic and Prognostic Guidelines.
Leung B; Aung H; Nandini A; Abdulrasool G; Lau C; Seymour L
J Mol Diagn; 2024 May; 26(5):399-412. PubMed ID: 38367765
[TBL] [Abstract][Full Text] [Related]
37. Integrating mutation variant allele frequency into clinical practice in myeloid malignancies.
Sallman DA; Padron E
Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):89-95. PubMed ID: 27187622
[TBL] [Abstract][Full Text] [Related]
38. Myeloid malignancies: mutations, models and management.
Murati A; Brecqueville M; Devillier R; Mozziconacci MJ; Gelsi-Boyer V; Birnbaum D
BMC Cancer; 2012 Jul; 12():304. PubMed ID: 22823977
[TBL] [Abstract][Full Text] [Related]
39. Clinical Utility of Implementing a Frontline NGS-Based DNA and RNA Fusion Panel Test for Patients with Suspected Myeloid Malignancies.
Bhai P; Hsia CC; Schenkel LC; Hedley BD; Levy MA; Kerkhof J; Santos S; Stuart A; Lin H; Broadbent R; Nan S; Yang P; Xenocostas A; Chin-Yee I; Sadikovic B
Mol Diagn Ther; 2022 May; 26(3):333-343. PubMed ID: 35381971
[TBL] [Abstract][Full Text] [Related]
40. Mutational profiling in patients with MDS: ready for every-day use in the clinic?
Bacher U; Kohlmann A; Haferlach T
Best Pract Res Clin Haematol; 2015 Mar; 28(1):32-42. PubMed ID: 25659728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
